Targeted vaccine adjuvants based on modified cholera toxin.
The present review describes immunomodulation with targeted adjuvants that will allow for the development of efficacious mucosal vaccines. We have studied cholera toxin (CT) and derivatives thereof, to rationally design vaccine adjuvant vectors that are both highly efficacious as well as safe and non-toxic. Two strategies were exploited; the first using CT or the enzymatically inactive receptor-binding B-subunit of CT (CTB) and the second, using CTA1 or an enzymatically inactive mutant CTA1R7K., that was linked, in a fusion protein, to the B-cell targeting moiety, DD, from Staphylococcus areus proteinA. Our studies provide compelling evidence that delivery of Ag in the absence of ADP-ribosylation can promote tolerance, whereas, ADP-ribosyltransferase-active conjugates, prevent tolerance but induce IgA immunity. Our analysis revealed unique subsets of mucosal and systemic DC that appeared to be responsible for the ADP-ribosyltransferase sensitive dichotomy between tolerance and IgA immunity. Whether targeting of B cells suffice for tolerance-induction or requires participation of DCs, is at present an unresolved issue. Nevertheless, enzymatic modulation differentiates and matures the DC to promote CD4 T cell help for IgA B cell development. Ag-presentation in the absence of enzyme, as seen with CTA1R7K-DD, expands specific T cells to a similar extent as enzymatically active CTA1-DD, but fails to recruit help for germinal center expansion of activated B cells. We have given special attention to the genes that adjuvants turn on using Affymetrix technology. In particular, modulation of the expression of co-stimulatory molecules on the targeted APC; CD80, CD86, CD83 and B7RP-1, play important roles for the effect of the ADP-ribosylating CTA1-based adjuvants for the development of tolerance or active IgA immunity.
Lycke
Nils
N
Department of Clinical Immunology, University of Göteborg, S413 46 Göteborg, Sweden. nils.lycke@microbio.gu.se
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D015703:Antigens, CD / Q000276:immunology / Q000378:metabolism; D051940:B7-2 Antigen; D002772:Cholera Toxin / Q000276:immunology*; D018928:Immunity, Mucosal / Q000276:immunology / Q000502:physiology; D007070:Immunoglobulin A / Q000276:immunology; D008562:Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism; D051379:Mice; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014612:Vaccines / Q000737:chemistry; D014614:Vaccines, Synthetic / Q000276:immunology*
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D051940:B7-2 Antigen; C440610:CTA1-DD protein, recombinant; C497965:Cd86 protein, mouse; D007070:Immunoglobulin A; D008562:Membrane Glycoproteins; D011993:Recombinant Fusion Proteins; D014612:Vaccines; D014614:Vaccines, Synthetic; D002772:Cholera Toxin